1. BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.

    "We are thrilled to recognize the appointment of Jared to General Counsel," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Since joining Entrada, Jared has been critical in leading our legal and compliance functions, guiding us through our recent financings and building a robust patent estate covering our innovative EEV platform and associated programs…

    BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.

    "We are thrilled to recognize the appointment of Jared to General Counsel," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Since joining Entrada, Jared has been critical in leading our legal and compliance functions, guiding us through our recent financings and building a robust patent estate covering our innovative EEV platform and associated programs. This appointment reflects his past contributions, and more importantly, our confidence in his potential to lead Entrada through our next phase of growth."

    Dr. Cohen has nearly 20 years of legal experience, with the majority of his career spent in the healthcare industry. Prior to joining Entrada in April 2020, Dr. Cohen was Vice President of Legal Affairs at Repertoire Immune Medicines where he designed and led all facets of the legal, compliance and intellectual property functions for the organization, including the transition through Series B, subsidiary acquisition and corporate merger. Prior to Repertoire, Dr. Cohen held a variety of leadership roles in the biopharmaceutical field, including Alexion Pharmaceuticals, The Jackson Laboratory, MedImmune/AstraZeneca, Human Genome Sciences, and Finnegan Henderson. Dr. Cohen earned his BS in Biology at Duke University, his PhD in Biochemistry, Molecular and Cell Biology from Cornell University and attended Cornell Law School.

    About Entrada Therapeutics

    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

    For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

    Entrada/Investor Contact

    Karla MacDonald

    VP, Corporate Communications and Investor Relations

    Media Contact

    Aulani Capuchin

    Real Chemistry



    (559) 355-2673

     



    Primary Logo

    View Full Article Hide Full Article
  2. BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes as part of the planned fourth quarter IPO additions, effective after the U.S. market opens on December 20, 2021.

    "The inclusion of Entrada Therapeutics in the Russell 2000® and Russell 3000® Indexes marks another notable milestone following the close of our successful IPO in November," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "As we continue to advance our…

    BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes as part of the planned fourth quarter IPO additions, effective after the U.S. market opens on December 20, 2021.

    "The inclusion of Entrada Therapeutics in the Russell 2000® and Russell 3000® Indexes marks another notable milestone following the close of our successful IPO in November," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "As we continue to advance our pipeline of EEV therapeutic candidates, we anticipate the inclusion will bring greater market awareness to our EEV platform and its potential to engage intracellular targets that have long been considered inaccessible and undruggable. We are very pleased to be part of the Russell indexes and look forward to broadening our visibility within the investment community."

    The Russell 2000® Index measures the performance of the small-cap segment of the US equity market. The Russell 2000® Index is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.

    Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.7 trillion in assets are benchmarked against Russell's U.S. indexes which are part of FTSE Russell, a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. For more information on the Russell Indexes, please visit the FTSE Russell website at https://www.ftserussell.com.

    About Entrada Therapeutics

    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

    For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada's strategy, future operations, prospects and plans, objectives of management, the potential of the EEV platform and the establishment of EEV therapeutics as a new class of medicines constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including but not limited to those identified and discussed in the section titled "Risk Factors" set forth in Part II, Item 1A of Entrada's most recent Quarterly Report on Form 10-Q, our other filings with the Securities and Exchange Commission (SEC), and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada's views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada's views as of any date subsequent to the date of this press release.

    Entrada/Investor Contact

    Karla MacDonald

    VP, Corporate Communications and Investor Relations

    Media Contact

    Aulani Capuchin

    Real Chemistry



    (559) 355-2673



    Primary Logo

    View Full Article Hide Full Article
  3. Successful completion of upsized $208.7 million Initial Public Offering

    BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent business updates.

    "This quarter has been transformational for Entrada as we made meaningful progress across all areas of our business, including the advancement of our pipeline of EEV therapeutic candidates," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "The successful…

    Successful completion of upsized $208.7 million Initial Public Offering

    BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent business updates.

    "This quarter has been transformational for Entrada as we made meaningful progress across all areas of our business, including the advancement of our pipeline of EEV therapeutic candidates," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "The successful close of our upsized initial public offering in November has placed us in a strong financial position to advance our lead neuromuscular candidate, ENTR-601-44, for patients with DMD who are exon 44 skipping amenable, through initial clinical data. The financing also enables us to move our second program, an EEV-PMO for patients with DM1, into clinical development as well as advance additional pipeline assets from our proprietary EEV platform."

    In November, Entrada completed an upsized Initial Public Offering (IPO) raising $208.7 million in gross proceeds. The Company closed its IPO, issuing a total of 10,436,250 shares of Entrada's common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,361,250 shares of common stock, at a public offering price of $20.00 per share. The net proceeds after deducting underwriting discounts, commissions and other estimated offering expenses were approximately $190.9 million.

    Third Quarter 2021 Financial Results

    Cash Position: As of September 30, 2021, cash and cash equivalents were $122.2 million. This amount does not include net proceeds from the November 2021 closing of the Company's IPO, which raised approximately $190.9 million, after deducting underwriting discounts, commissions and other estimated offering costs.

    Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2021 were $10.5 million as compared to $5.7 million for the same period in 2020. This increase was primarily due to additional investment in preclinical studies to support future clinical trials, and higher personnel costs (including non-cash stock-based compensation).

    General & Administrative (G&A) Expenses: G&A expenses for the third quarter of 2021 were $3.9 million as compared to $1.3 million for the same period in 2020. This increase was primarily due to higher personnel costs (including non-cash stock-based compensation), legal and other professional fees, and facilities costs.

    Net Loss: Net loss for the third quarter of 2021 was $14.4 million, compared to $7.0 million for the third quarter of 2020.

    About Entrada Therapeutics

    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

    For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada's strategy, future operations, prospects and plans, objectives of management, the potential of the EEV platform and the establishment of EEV therapeutics as a new class of medicines, the advancement of ENTR-601-44 through initial clinical data, the movement of an EEV-PMO candidate for the treatment of DM1 into clinical development, the potential therapeutic benefits of its EEV candidates and the sufficiency of its cash resources, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and Entrada's ability to submit and obtain regulatory clearance for investigational new drug applications and initiate clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether Entrada's cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties associated with the impact of the COVID-19 pandemic on Entrada's business and operations; as well as the risks and uncertainties identified in Entrada's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-Q and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada's views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada's views as of any date subsequent to the date of this press release.



    ENTRADA THERAPEUTICS, INC.

    SELECTED CONDENSED FINANCIAL INFORMATION

    (In thousands, except share and per share amounts)

    (unaudited)

    Condensed statements of operations                
      Three Months Ended September 30, Nine Months Ended September 30,

      2021 2020 2021 2020
                 
    Operating expenses:            
    Research and development $10,513  $5,700  $23,564  $14,446 
    General and administrative  3,851   1,273   9,103   3,568 
    Total operating expenses  14,364   6,973   32,667   18,014 
    Loss from operations  (14,364)  (6,973)  (32,667)  (18,014)
    Other income (expense):            
    Interest and other income (expense), net  (66)  (17)  (44)  164 
    Total other income (expense), net  (66)  (17)  (44)  164 
    Net loss $(14,430) $(6,990) $(32,711) $(17,850)
    Net loss per share attributable to common stockholders, basic and diluted $(9.78) $(6.13) $(24.18) $(16.55)
    Weighted-average common shares outstanding, basic and diluted  1,475,170   1,139,647   1,352,721   1,078,783 



    Condensed balance sheets      
      September 30,  December 31, 
      2021 2020
             
    Cash and cash equivalents $122,172  $39,045 
    Total assets  132,395   43,527 
    Total liabilities  7,497   3,359 
    Redeemable convertible preferred stock  197,489   81,658 
    Total stockholders' deficit  (72,591)  (41,490)
             

    Entrada/Investor Contact

    Karla MacDonald

    VP, Corporate Communications and Investor Relations

    Media Contact

    Aulani Capuchin

    Real Chemistry



    (559) 355-2673



    Primary Logo

    View Full Article Hide Full Article
  4. BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biotechnology company aiming to transform the lives of patients and become the world's foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time.

    A live webcast will be available on the Investor Relations section of the Company's website at www.entradatx.com, or by clicking here. A replay will be available on the Entrada website for 90 days following…

    BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biotechnology company aiming to transform the lives of patients and become the world's foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time.

    A live webcast will be available on the Investor Relations section of the Company's website at www.entradatx.com, or by clicking here. A replay will be available on the Entrada website for 90 days following the event.

    About Entrada Therapeutics

    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

    Entrada/Investor Contact

    Karla MacDonald

    VP, Corporate Communications

    Media Contact

    Aulani Capuchin

    Real Chemistry



    (559) 355-2673



    Primary Logo

    View Full Article Hide Full Article
  5. BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world's foremost intracellular therapeutics company, today announced the closing of its initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share. All shares were offered by Entrada. The gross proceeds to Entrada from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $181.5 million. The shares began trading on The Nasdaq Global Market under the ticker symbol "TRDA" on October…

    BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world's foremost intracellular therapeutics company, today announced the closing of its initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share. All shares were offered by Entrada. The gross proceeds to Entrada from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $181.5 million. The shares began trading on The Nasdaq Global Market under the ticker symbol "TRDA" on October 29, 2021. In addition, the underwriters have a 30-day option to purchase up to an additional 1,361,250 shares of common stock at the initial public offering price less underwriting discounts and commissions.

    Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering.

    A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 28, 2021. The offering was made only by means of a written prospectus. Copies of the final prospectus relating to the initial public offering can be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing ; Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at or by telephone at (833) 297-2926; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Entrada Therapeutics

    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

    Entrada/Investor Contact

    Karla MacDonald

    VP, Corporate Communications

    Media Contact

    Aulani Capuchin

    Real Chemistry



    (559) 355-2673



    Primary Logo

    View Full Article Hide Full Article